FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens

기사 요약

FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.